What is Enliven Therapeutics's depreciation?

Enliven Therapeutics (ELVN) reported depreciation of $14K in Q1 2026.

How has Enliven Therapeutics's depreciation changed year-over-year?

Enliven Therapeutics's depreciation decreased by 81.1% year-over-year, from $74K to $14K.

Over 4 years (2021 to 2025), Enliven Therapeutics's depreciation has grown at a 27.7% compound annual growth rate (CAGR), from $99K to $263K.

Jazz PharmaceuticalsJAZZ

——

Operating income-$27.8M+12.2%

Net income-$23.6M+17.2%

EPS (diluted)-$0.38+33.3%

Cash & equivalents$132.2M+30.0%

Total debt$302.0K-56.9%

Total equity$453.4M+57.3%

Total assets$464.9M+53.6%

Operating cash flow-$19.3M+20.0%

CapEx--100%

Free cash flow-$19.3M+20.1%

Market cap$3.47B+143%

Enterprise value$3.34B+156%

Return on equity-26.6%-3.5pp

Debt / equity0×0.0×

Current ratio40.3×+19.3×

Reported directly by Enliven Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Enliven Therapeutics's depreciation?: Enliven Therapeutics (ELVN) reported depreciation of $14K in Q1 2026.
How has Enliven Therapeutics's depreciation changed year-over-year?: Enliven Therapeutics's depreciation decreased by 81.1% year-over-year, from $74K to $14K.
What is the long-term trend for Enliven Therapeutics's depreciation?: Over 4 years (2021 to 2025), Enliven Therapeutics's depreciation has grown at a 27.7% compound annual growth rate (CAGR), from $99K to $263K.